Estimated Disease Burden of COVID-19

Updated Dec. 7, 2020

On This Page

What can be learned from estimates of COVID-19 infections, illnesses, and hospitalizations in the United States
Why CDC Estimates COVID-19 Infections, Illnesses, and Hospitalizations
How CDC Estimates COVID-19 Infections, Symptomatic Illnesses and Hospitalizations
Limitations

To better reflect the burden of COVID-19 – the full impact of the disease — CDC provides estimates of COVID-19 infections, symptomatic illnesses, and hospitalizations using a statistical model to adjust for cases that national surveillance networks are unable to capture for a number of reasons. These estimates and the methodology used to calculate them are published in Clinical Infectious Diseases and available onlineexternal icon. These estimates will be updated periodically.

Estimated COVID-19 Infections, Symptomatic Illnesses, and Hospitalizations—United States

CDC estimates that from February–September 2020:

1 in 2.5 (95% UI* 2.0 - 3.1) COVID-19 hospitalizations were reported

1 in 7.1 (95% UI* 5.8 - 9.0) COVID-19 symptomatic illnesses were reported

1 in 7.7 (95% UI* 6.2 - 9.7) total COVID-19 infections were reported

These estimates suggest that during that period, there were approximately:

53 Million

Estimated Total Infections

45 Million

Estimated Symptomatic Illnesses

2.4 Million

Estimated Hospitalizations

Last Updated: November 25, 2020

Table 1: Preliminary Estimated COVID-19 Cumulative Incidence, by age group — United States, February- September 2020

	Infections		Symptomatic Illness		Hospitalizations
Age group	Estimate	95% UI*	Estimate	95% UI*	Estimate	95% UI*
0-4 yrs	1,342,212	1,022,465 – 1,811,583	1,144,532	903,194 – 1,500,315	20,719	16,595 – 26,069
5-17 yrs	5,538,766	4,222,053 – 7,451,900	4,719,785	3,722,649 – 6,177,733	44,321	33,300 – 58,552
18-49 yrs	29,421,48	21,798,393 – 41,330,693	25,096,725	19,137,381 – 34,524,124	652,741	530,955 – 823,453
50-64 yrs	10,484,802	7,860,849 – 14,346,364	8,926,318	6,873,250 – 11,928,318	642,358	538,092 – 778,266
65+ yrs	5,636,607	4,139,528 – 8,024,420	4,556,384	3,569,223 – 6,172,269	1,022,295	826,438 – 1,361,730
All ages	52,885,526	42,527,569 – 66,810,205	44,769,417	36,920,353 – 55,535,659	2,397,777	2,053,156 – 2,855,843

* Adjusted estimates and rates are presented in two parts: an uncertainty interval [UI] and a point estimate. The uncertainty interval provides a range in which the true number or rate of COVID-19 hospitalization would be expected to fall if the same study was repeated many times, and it gives an idea of the precision of the point estimate. A 95% uncertainty interval means that if the study were repeated 100 times, then 95 out of 100 times the uncertainty interval would contain the true point estimate. Conversely, in only 5 times out of a 100 would the uncertainty interval not contain the true point estimate.

Table 2: Estimated rates of COVID-19 disease outcomes, per 100,000, by age group — United States, February- September 2020

	Infection rate per 100,000		Symptomatic Illness rate per 100,000		Hospitalization rate per 100,000
Age group	Estimate	95% UI*	Estimate	95% UI*	Estimate	95% UI*
0-4 yrs	6,775	5,161 – 9,145	5,777	4,559 – 7,573	105	84 – 132
5-17 yrs	10,336	7,879 – 13,906	8,807	6,947 – 11,528	83	62 – 109
18-49 yrs	21,292	15,775 – 29,911	18,162	13,850 – 24,985	472	384 – 596
50-64 yrs	16,601	12,446 – 22,715	14,133	10,883 – 18,887	1,017	852 – 1,232
65+ yrs	10,750	7,895 – 15,305	8,690	6,807 – 11,772	1,950	1,576 – 2,597
All ages	16,165	12,999 – 20,421	13,684	11,285 – 16,975	733	628 – 873

Percentage of COVID-19 infections, symptomatic illness, and hospitalizations by age group

Estimating unreported cases helps to quantify the impact and severity of the COVID-19 pandemic on the healthcare system and society. Additionally, these estimates can inform how to direct and allocate hospital resources; assist in planning for prevention and control measures, including vaccination; predict the future burden of COVID-19; and evaluate the potential impact of interventions.

The cumulative incidence of COVID-19 is an estimate of the number of people who may have been infected, sick, or hospitalized as a result of a COVID-19 infection from February to September 30, 2020. In the United States, confirmed COVID-19 cases are nationally reported, but these cases likely represent only a fraction of the true number of cases that have occurred in the population. COVID-19 infections, symptomatic illnesses, and hospitalizations may be under detected and go unreported for a variety of reasons:

Some people infected with SARS-CoV-2 may never show symptoms (asymptomatic infection), so their infection will likely go undetected.
Case reports sent to CDC are often missing patient information, like age or hospitalization status, or are delayed.
Not everyone who is sick will seek medical care and/or be tested; and patients may not be tested for COVID-19 while hospitalized.
Even if a sick outpatient or hospitalized patient is tested, an infection with COVID-19 may not be accurately captured if:
- the test was not completed correctly, or within the appropriate timeframe for capturing infection;
- the test result was falsely negative for a COVID-19 infection due to the sensitivity of the test;
- the test result was falsely negative for a COVID-19 infection due to the quality or quantity of the specimen collected;
- or the confirmed COVID-19 case was never reported to the local and state public health agency and then to CDC.

Because current surveillance systems do not capture all cases of COVID-19 occurring in the United States, CDC provides these estimates to better reflect the larger burden of COVID-19. CDC uses these types of estimates to inform policy decisions and public messages.

COVID-19 infections, symptomatic illnesses, and hospitalizations are estimated using a statistical model applied to confirmed cases of COVID-19, adjusted for missing age and hospitalization status. Several data sources and surveillance systems are used to identify and characterize potential sources of under-detection, which include:

SARS-CoV-2 test sensitivity. People tested for SARS-CoV-2, the virus that causes COVID-19 disease, may not test positive even if infected with the virus due to the lower sensitivity of the test used. SARS-CoV-2 test sensitivity has been reported in the literature; a range of 79-98% sensitivity is used to account for false negative test results.

- SARS-CoV-2 test ordered and completed in a timely manner. Not all outpatients who seek care for acute respiratory illness (ARI) and inpatients hospitalized with ARI were tested for COVID-19, and not all ordered tests were correctly completed in a timely manner. Two data sources were used to approximate how many outpatients with ARI were not tested for COVID-19:
  - IBM Watson Explorys Electronic Health Record database, a data repository of electronic health records from more than 39 health partners, 400 acute care facilities, and 400,000 unique providers; and
  - COVID Near Youexternal iconexternal icon (CNY), a website application launched by Harvard University in March 2020 where participants can submit information on self-reported symptoms, efforts to obtain health care, and COVID-19 testing.
- Symptomatic patient may or may not seek care or testing services. Not all sick patients will seek care and/or be tested for COVID-19, and therefore are not included in national case reports. To approximate the number of symptomatic people who never sought medical care, researched used data from COVID Near Youexternal icon (CNY) and Flu Near Youexternal icon (FNY) sites on health care seeking behaviors. While COVID Near You launched in March 2020, FNY has been collecting self-reported influenza participatory data since 2011.
- Case is asymptomatic. Some people infected with SARS-CoV-2 may never show symptoms (asymptomatic infection) so are very likely to go undetected. The percentage of asymptomatic infections is reported in the literature and varies by age group. In those 0-64 years old a range of 5-24% is used, and for those 65 years and older, a range of 5-32% is used.

The statistical model used to adjust hospitalized and non-hospitalized case counts for the above sources of under-detection is based on methods that have been previously used to estimate the disease burden of influenza, detailed elsewhere.

These estimates of COVID-19 infections, symptomatic illnesses, and hospitalizations are subject to several limitations.

In the early stages of the COVID-19 pandemic, as is generally the case with the emergence of a novel virus like SARS-CoV-2, data on testing, detection, and case reporting, which are necessary for estimating the true burden of a disease were lacking or not available. More specifically, in some heavily affected areas of the United States, the size of the COVID-19 outbreak quickly exceeded the capacity of health systems to complete detailed reporting on cases that included information like the age of the patient and whether or not they were hospitalized. This led to case reports sent to CDC that were missing vital patient information. CDC had to estimate the age and hospitalization status of patients with missing data based on cases with known information on age and hospitalization status. To inform how to make estimates of disease burden for COVID-19, we relied on our experiences estimating influenza disease burden. CDC has been monitoring testing practices for influenza (flu) among hospitalized patients since 2010 to make estimates of annual disease burden of flu in the United States. Nearly a decade of flu data collection and analysis has shown respiratory disease testing varies in different parts of the country, by care settings, for different age groups, and at differing levels of disease severity. The data available so far on COVID-19 testing practices are limited across these variables. Once more complete data across these variables are available, COVID-19 burden estimates will be updated.

As additional data become available on the sensitivity of the SARS-CoV-2 tests, these data will also help refine COVID-19 infection, illness, and hospitalization estimates.

Last Updated Dec. 7, 2020

Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases